Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The Heart-SCC Puzzle

Olga Kaloudi, MD, and Marco Matucci Cerinic, MD, PhD  |  Issue: May 2009  |  May 1, 2009

In SSc, the incidence of sudden cardiac death is higher than that in the general population. Postmortem studies of SSc patients who die suddenly show a history of ventricular arrhythmias, documented ventricular tachycardias, and frequent multifocal premature ventricular contractions.4 Currently, there is no evidence that drug therapy lowers mortality in SSc patients. In fact, the outcome may be even worse with treatment because of a proarrythmic effect of drugs; the use of drugs, however, may represent a marker of severity of arrhythmia rather than a cause of increased mortality. Whatever the basis for this association, these data suggest that use of anti-arrhythmics in SSc patients should be closely monitored with repeated ambulatory electrocardiography.

Figure 1: An algorithm for the diagnosis and management of cardiac involvement in SSc.
click for large version
Figure 1: An algorithm for the diagnosis and management of cardiac involvement in SSc.

Diagnosis

1) Standard 12-lead electrocardiogram (EKG): At baseline, a standard 12-lead EKG with serial studies at intervals is the most simple, inexpensive, and rapid method for initial cardiac evaluation (see Figure 1, p.17). In SSc, an EKG can detect hidden arrhythmias, asymptomatic conduction defects, and previous ischemic defects. In a large EKG study, ventricular ectopy occurred in 67% of patients and was strongly correlated with total mortality and sudden death, independently from other indexes of severity of disease and organ involvement.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

2) Holter monitoring: Holter monitoring is a non-invasive method with high predictive value that permits the early detection of cardiac involvement. Analysis of Holter monitoring data can detect arrhythmias and conduction defects not seen on a standard EKG. Patients with significant abnormalities on Holter monitoring should have further investigations (see Figure 1, p.17). In SSc, Holter monitoring may add valuable information about the autonomic nervous system, assessing the heart rate variability and the QT interval. Recently, abnormalities of heart rate variability and increased QT dispersion have been reported in SSc patients. Autonomic dysfunction represents the cardiac vulnerability resulting from an autonomic imbalance and is a marker for arrhythmic death or an indicator of disease severity. We strongly recommend performance of a Holter at least twice a year in patients with SSc.

3) Invasive electrophysiologic studies: Invasive electrophysiologic studies are indicated when spontaneous arrhythmias are frequent and when a serious sustained arrhythmia is suspected. Electrophysiologic studies can detect the mechanism generating the arrhythmias and allow the selection of patients who can be treated by transcatheter ablation; in this selection, the guidelines are similar to those employed in the management for ventricular tachycardia due to coronary disease.5

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Treatment

At present, the management of cardiac involvement in SSc remains largely empirical and derives mainly from evidence obtained from other diseases. There is no evidence that anti-arrhytmic drug therapy lowers mortality in SSc patients. Successful treatment with ablation, both surgical cryoablation and catheter ablation, has been reported. Implantation of a cardioverter defibrillator and/or a pacemaker may be a treatment of choice for patients with life-threatening ventricular arrhythmias and conduction defects.

Figure 2: A Holter surface EKG with complex ventricular tachycardia before ICD implantation.
Figure 2: A Holter surface EKG with complex ventricular tachycardia before ICD implantation.

Myocardial Piece of the Puzzle

Primary myocardial involvement in SSc is characterized by patchy fibrotic lesions distributed in both ventricles. Although advanced myocardial fibrosis may lead to congestive heart failure, systolic or diastolic dysfunction can occur early in the disease, before becoming symptomatic years later. When clinically evident, myocardial involvement is recognized as a poor prognostic factor since the overall mortality rate at five years of SSc patients with proven cardiovascular impairment is over 70%. Usually, physical findings are nonspecific and include signs of congestive heart failure. For this reason, a timely diagnosis is highly recommended.

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:ConditionsSystemic Sclerosis Tagged with:CardiacDiagnosisSystemic sclerosisTreatment

Related Articles

    Capillaroscopy a Safe and Direct Method for SSc Diagnosis

    June 13, 2011

    Seeing vessels clearly can help with discovery and timely treatment

    Scleroderma & ILD: Practical Tips on the Diagnosis & Management of Systemic Sclerosis-Associated Interstitial Lung Disease

    June 15, 2022

    No one-size-fits-all approach exists for the care and treatment of patients with systemic sclerosis (SSc) and SSc with pulmonary involvement. Here, experts discuss some best clinical practices for these patients.

    Labored Breathing

    January 1, 2007

    Strategies to diagnose and manage dyspnea in the scleroderma patient

    Progress Continues in Systemic Sclerosis

    March 1, 2010

    Advances in genetics and potential therapies shed new light on the disease

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences